New clinical studies show benefit of CardioQ-ODM

RNS Number : 4863H

Deltex Medical Group PLC

31 May 2011

 



Deltex Medical Group plc

Four new clinical studies show benefit of CardioQ-ODM

31 May 2011 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), notes new clinical studies presented at international clinical meetings in May that demonstrate benefit from use of the CardioQ-ODM during major and high risk surgery.

1.       In Hong Kong, UK doctors presented analysis of outcomes over a two year period for patients undergoing laparoscopic (key-hole) prostate and bladder surgery combined with use of CardioQ-ODM within an enhanced recovery programme. Use of CardioQ-ODM was associated with hospital length of stay reductions in excess of 30% for bladder surgery and of nearly 50% for prostate surgery.

2.       In the USA, another group of UK doctors presented trial data showing that patients undergoing major bladder surgery treated with CardioQ-ODM suffered significantly less post-operative nausea and vomiting and recovered normal gut function more quickly.

3.       In Ireland, a third group of UK doctors presented data using CardioQ-ODM in colorectal surgery. Their trial did not show any statistically significant overall change in length of hospital stay but did report that patients treated with CardioQ-ODM suffered 25% fewer severe complications. A team of Irish doctors presented early audit data showing that using CardioQ-ODM during laparoscopic colorectal surgery significantly reduced post-operative complications and reduced length of hospital stay.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"The further evidence of the clinical benefit of CardioQ-ODM provided by these new studies reinforces the recent recommendation from the National Institute of Health and Clinical Excellence (NICE). The studies demonstrate that use of CardioQ-ODM is just as beneficial to patients today undergoing the most sophisticated and modern approaches to major surgery as in traditional approaches.

"Use of CardioQ-ODM is increasingly regarded as a modern standard of care in bowel surgery: an accumulation of evidence of benefit in urological surgery should facilitate and accelerate expansion of use of our products in those hospitals around the world already introducing use of CardioQ-ODM into bowel surgery."

For further information, please contact:-

Deltex Medical Group plc                                    01243 774 837

Nigel Keen, Chairman                                          [e-mail]

Ewan Phillips, Chief Executive                            [e-mail]

Paul Mitchell, Finance Director                            [e-mail]

Nominated Adviser & Broker

Arden Partners plc                                             020 7614 5900

Chris Hardie                                                        [e-mail]

Jamie Cameron                                                   [e-mail]

Kreab Gavin Anderson                                       020 7074 1800

Robert Speed                                                      [e-mail]

Deborah Walter                                                   [e-mail]

Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODMÔ system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world.

CardioQ-ODM comprises a monitor and a single patient disposable probe. The probe is placed into the oesophagus through either the mouth or nose and the tip positioned facing the adjacent descending aorta. A low frequency ultrasound signal, generated by the monitor, is bounced off the blood travelling down the aorta and the Doppler principle is used to determine the velocity of the blood flow, expressed in distance per cardiac cycle - 'Stroke Distance'. The monitor also calculates the amount of time that blood is flowing down the aorta as a proportion of a cardiac cycle - 'Flow Time'.

The monitor uses a validated proprietary nomogram to extrapolate volumetric data (Stroke Volume, Cardiac Output etc) from the directly measured flow velocity. The nomogram utilises the patient's age weight and height, effectively to estimate the size of the aorta in which the velocity of the flow is being measured. Crucially this means that any reported relative change in Stroke Volume is absolutely identical to the relative change in the directly measured flow velocity variable of Stroke Distance. CardioQ-ODM immediately and reliably identifies even very small changes in the blood flow velocity allowing doctors to intevene earlier and on smaller changes than with any other approach.

Intra-operative individualised Doppler guided fluid management entails insertion and focusing of the probe to obtain a baseline reading, giving a small (200 to 250 ml) fluid challenge directly into the vascular system and seeing if Stroke Volume (or Stroke Distance) increases by more than 10%. If the increase is more than 10%, repeat fluid boluses are administered until such time as the increase is less than 10%: after this no further fluid is given unless Stroke Volume falls by more than 10% - the process is designed to achieve and maintain the individual patient's optimal Stroke Volume. CardioQ-ODM is also used during surgery to guide administration of vaso-active agents such as inotropes.

The CardioQ-ODM helps patients by enabling doctors to reduce the complications that arise from a medical condition that is common to almost all patients having surgery and many others in intensive care or arriving in the accident and emergency department. This condition is known as hypovolaemia - a reduction in circulating blood volume - and in surgical patients arises as a direct consequence of the combined effects of pre-operative starvation, the anaesthetic agents and the blood and fluid losses associated with the surgical procedure itself. Hypovolaemia means that the body struggles to get sufficient blood to the tissues and vital organs which are consequently starved of essential oxygen. This can cause medical complications including peripheral and major organ failure, which if not dealt with quickly can lead to severe compromise or even death.

There are already over 2,300 CardioQ-ODMscurrently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 250 clinical publications on the use of the CardioQ-ODM which have repeatedly:-

·    Validated the results of CardioQ-ODMagainst known standards for measuring cardiac output

·    Proved that CardioQ-ODM works in a wide range of surgical procedures

·    Proved that CardioQ-ODMdelivers 50% or more reductions in post-operative complications and 25% or more reductions in length of hospital stay: better care at lower cost.

The SupraQÔis an entirely non-invasive device which uses an ultrasound probe held at the base of the patient's neck to track the flow of blood in the aorta; it presents the same data as the CardioQ-ODMin a similar format and is used for taking snapshots or monitoring over short periods.

 

END

 

 

NRABLGDUDBDBGBR